Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide + BPaL in Drug-susceptible Pulmonary Tuberculosis
NCT07517445Phase 2Suspended
- Sponsor
- Gates Medical Research Institute
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide in Tuberculosis (TB), sponsored by Gates Medical Research Institute. Started Apr 2026; status: suspended.
02
Drugs
nicotinamide
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07517445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07517445.